英哈
结核分枝杆菌
效力
异烟肼
化学
肺结核
药物发现
体内
还原酶
微生物学
酶
药理学
生物化学
体外
生物
医学
生物技术
病理
作者
Lourdes Encinas,Heather P. O’Keefe,Margarete Neu,Modesto Jesús Remuiñán,Amish Patel,Ana Carolina Guardia,Christopher P. Davie,Natalia Pérez-Macías,Hongfang Yang,M.A. Convery,Jeffrey A. Messer,Esther Pérez‐Herrán,Paolo A. Centrella,Daniel Álvarez-Gómez,Matthew Clark,Sophie Huss,Gary K. O’Donovan,Fátima Ortega-Muro,William McDowell,Pablo Castañeda
摘要
Tuberculosis (TB) is one of the world's oldest and deadliest diseases, killing a person every 20 s. InhA, the enoyl-ACP reductase from Mycobacterium tuberculosis, is the target of the frontline antitubercular drug isoniazid (INH). Compounds that directly target InhA and do not require activation by mycobacterial catalase peroxidase KatG are promising candidates for treating infections caused by INH resistant strains. The application of the encoded library technology (ELT) to the discovery of direct InhA inhibitors yielded compound 7 endowed with good enzymatic potency but with low antitubercular potency. This work reports the hit identification, the selected strategy for potency optimization, the structure-activity relationships of a hundred analogues synthesized, and the results of the in vivo efficacy studies performed with the lead compound 65.
科研通智能强力驱动
Strongly Powered by AbleSci AI